Published in Am J Ophthalmol on December 04, 2012
Ocular delivery of macromolecules. J Control Release (2014) 0.91
Clinical characteristics and current treatment of age-related macular degeneration. Cold Spring Harb Perspect Med (2014) 0.87
Age-Related Macular Degeneration: Advances in Management and Diagnosis. J Clin Med (2015) 0.87
Antagonism of PDGF-BB suppresses subretinal neovascularization and enhances the effects of blocking VEGF-A. Angiogenesis (2013) 0.86
Potent and specific inhibition of glycosidases by small artificial binding proteins (affitins). PLoS One (2014) 0.82
Novel pharmacotherapies in diabetic retinopathy: Current status and what's in the horizon? Indian J Ophthalmol (2016) 0.82
Treatment of diabetic retinopathy: Recent advances and unresolved challenges. World J Diabetes (2016) 0.79
Diabetic Retinopathy: Animal Models, Therapies, and Perspectives. J Diabetes Res (2016) 0.79
NextGen protein design. Biochem Soc Trans (2013) 0.78
Updates in the management of diabetic macular edema. J Diabetes Res (2015) 0.77
Novel ubiquitin-derived high affinity binding proteins with tumor targeting properties. J Biol Chem (2014) 0.76
Extremophilic 50S Ribosomal RNA-Binding Protein L35Ae as a Basis for Engineering of an Alternative Protein Scaffold. PLoS One (2015) 0.75
The role of aflibercept in the management of diabetic macular edema. Drug Des Devel Ther (2015) 0.75
Ranibizumab for neovascular age-related macular degeneration. N Engl J Med (2006) 30.63
Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med (2006) 20.84
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology (2012) 8.29
Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology (2009) 6.44
Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology (2012) 6.35
Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology (2006) 5.79
Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol (2008) 5.22
Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology (2010) 4.09
A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology (2009) 3.76
Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology (2010) 3.49
High-affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol (2004) 3.34
Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol (2007) 3.00
Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. J Mol Biol (2003) 2.81
Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology (2011) 2.78
Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina (2008) 2.72
Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema. Ophthalmology (2007) 2.58
Oct-based interpretation of the vitreomacular interface and indications for pharmacologic vitreolysis. Retina (2013) 2.49
The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci (2005) 2.35
Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology (2012) 2.32
Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol (2012) 2.30
Oxidative stress and calcium signaling in the adverse effects of environmental particles (PM10). Free Radic Biol Med (2003) 2.28
One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology (2012) 2.20
Signal sequences directing cotranslational translocation expand the range of proteins amenable to phage display. Nat Biotechnol (2006) 2.18
A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology (2006) 2.17
Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. Br J Ophthalmol (2013) 2.14
Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology (2013) 2.13
Inspiratory loading intensity does not influence lactate clearance during recovery. Med Sci Sports Exerc (2012) 2.00
RANIBIZUMAB PLUS PROMPT OR DEFERRED LASER FOR DIABETIC MACULAR EDEMA IN EYES WITH VITRECTOMY BEFORE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. Retina (2015) 1.99
Designed to be stable: crystal structure of a consensus ankyrin repeat protein. Proc Natl Acad Sci U S A (2003) 1.98
Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology (2012) 1.95
Absence of branches from xylan in Arabidopsis gux mutants reveals potential for simplification of lignocellulosic biomass. Proc Natl Acad Sci U S A (2010) 1.88
The role of free radicals in the toxic and inflammatory effects of four different ultrafine particle types. Inhal Toxicol (2003) 1.83
Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology (2011) 1.79
SAVE (Super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results. Ophthalmic Surg Lasers Imaging Retina (2013) 1.60
Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res (2009) 1.58
Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmol (2013) 1.55
Encephalitis and myelitis associated with dengue viral infection clinical and neuroimaging features. Clin Neurol Neurosurg (2008) 1.53
Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res (2010) 1.51
The impact of different nanoparticle surface chemistry and size on uptake and toxicity in a murine macrophage cell line. Toxicol Appl Pharmacol (2008) 1.50
Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology (2012) 1.48
Synthetic generation of influenza vaccine viruses for rapid response to pandemics. Sci Transl Med (2013) 1.47
Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci U S A (2011) 1.47
Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the "flying saucer" sign). Clin Ophthalmol (2010) 1.43
Workflow comparison for label-free, quantitative secretome proteomics for cancer biomarker discovery: method evaluation, differential analysis, and verification in serum. J Proteome Res (2010) 1.42
Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology (2006) 1.37
The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology (2011) 1.34
Designed armadillo repeat proteins as general peptide-binding scaffolds: consensus design and computational optimization of the hydrophobic core. J Mol Biol (2007) 1.33
Folding of a designed simple ankyrin repeat protein. Protein Sci (2004) 1.20
Expression of angiopoietin-2 in endothelial cells is controlled by positive and negative regulatory promoter elements. Arterioscler Thromb Vasc Biol (2004) 1.20
Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. Ophthalmology (2011) 1.18
Cystoid macular edema secondary to albumin-bound paclitaxel therapy. Arch Ophthalmol (2008) 1.18
Retinal thickness in people with diabetes and minimal or no diabetic retinopathy: Heidelberg Spectralis optical coherence tomography. Invest Ophthalmol Vis Sci (2012) 1.17
Intracellular kinase inhibitors selected from combinatorial libraries of designed ankyrin repeat proteins. J Biol Chem (2005) 1.17
Implantable miniature telescope for the treatment of visual acuity loss resulting from end-stage age-related macular degeneration: 1-year results. Ophthalmology (2006) 1.17
A novel strategy to design binding molecules harnessing the modular nature of repeat proteins. FEBS Lett (2003) 1.15
Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two-year outcomes. Ophthalmology (2010) 1.13
Emerging roles of the Angiopoietin-Tie and the ephrin-Eph systems as regulators of cell trafficking. J Leukoc Biol (2006) 1.11
Evaluating the uptake and intracellular fate of polystyrene nanoparticles by primary and hepatocyte cell lines in vitro. Toxicol Appl Pharmacol (2009) 1.09
Detection of new-onset choroidal neovascularization using optical coherence tomography: the AMD DOC Study. Ophthalmology (2012) 1.09
An investigation into the potential for different surface-coated quantum dots to cause oxidative stress and affect macrophage cell signalling in vitro. Nanotoxicology (2010) 1.08
Angiopoietin-2 stimulation of endothelial cells induces alphavbeta3 integrin internalization and degradation. J Biol Chem (2010) 1.08
Wide-field retinal imaging in the management of noninfectious posterior uveitis. Am J Ophthalmol (2012) 1.08
Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology (2010) 1.06
GUX1 and GUX2 glucuronyltransferases decorate distinct domains of glucuronoxylan with different substitution patterns. Plant J (2013) 1.06
Blast eye injuries: a review for first responders. Disaster Med Public Health Prep (2010) 1.06
Early experience with intravitreal bevacizumab combined with laser treatment for retinopathy of prematurity. Middle East Afr J Ophthalmol (2010) 1.03
Prospective study of changes in bone mineral density and turnover in children after hematopoietic cell transplantation. J Clin Endocrinol Metab (2005) 1.02
CD5+ B cells from individuals with systemic lupus erythematosus express granzyme B. Eur J Immunol (2010) 1.02
The effects of serum on the toxicity of manufactured nanoparticles. Toxicol Lett (2010) 1.02
Changing patterns and outcome of Dengue infection; report from a tertiary care hospital in Pakistan. J Pak Med Assoc (2008) 1.01
Angiopoietin-2 is critical for cytokine-induced vascular leakage. PLoS One (2013) 0.99
Consensus design of repeat proteins. Chembiochem (2004) 0.98
Preferential Hyperacuity Perimeter (PreView PHP) for detecting choroidal neovascularization study. Ophthalmology (2005) 0.98
Mycophenolate mofetil and fundus autofluorescence in the management of recurrent punctate inner choroidopathy. Ocul Immunol Inflamm (2011) 0.96
Ultra-wide-field retinal imaging in the management of non-infectious retinal vasculitis. J Ophthalmic Inflamm Infect (2013) 0.95
Disparities in access to surgical care within a lower income country: an alarming inequity. World J Surg (2013) 0.95
Quantum dot cytotoxicity in vitro: an investigation into the cytotoxic effects of a series of different surface chemistries and their core/shell materials. Nanotoxicology (2010) 0.95
Precise montaging and metric quantification of retinal surface area from ultra-widefield fundus photography and fluorescein angiography. Ophthalmic Surg Lasers Imaging Retina (2014) 0.93
Organization of a United States county system for comprehensive acute stroke care. Stroke (2012) 0.91
Associated factors and comorbidities in patients with pyoderma gangrenosum in Germany: a retrospective multicentric analysis in 259 patients. Orphanet J Rare Dis (2013) 0.91
Endophthalmitis after intravitreal injection: the importance of viridans streptococci. Retina (2011) 0.89
Triphendiol (NV-196), development of a novel therapy for pancreatic cancer. Anticancer Drugs (2011) 0.89
A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF. Mol Immunol (2006) 0.89
Development of a population suppression strain of the human malaria vector mosquito, Anopheles stephensi. Malar J (2013) 0.88
Relating the physicochemical characteristics and dispersion of multiwalled carbon nanotubes in different suspension media to their oxidative reactivity in vitro and inflammation in vivo. Nanotoxicology (2010) 0.88
Ultrafine particles cause cytoskeletal dysfunctions in macrophages: role of intracellular calcium. Part Fibre Toxicol (2005) 0.88
The effect of refurbishing a UK steel plant on PM10 metal composition and ability to induce inflammation. Respir Res (2005) 0.88
Therapeutic interference with EphrinB2 signalling inhibits oxygen-induced angioproliferative retinopathy. Acta Ophthalmol (2011) 0.88
Use of nepafenac (Nevanac) in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections. Clin Ophthalmol (2010) 0.87
Preoperative visual acuity as a prognostic indicator for laser treatment of macular edema due to branch retinal vein occlusion. Ophthalmic Surg Lasers Imaging (2006) 0.86
Antagonism of PDGF-BB suppresses subretinal neovascularization and enhances the effects of blocking VEGF-A. Angiogenesis (2013) 0.86
Angiopoietin-1 mediates inhibition of hypertension-induced release of angiopoietin-2 from endothelial cells. Cardiovasc Res (2012) 0.86
Affilin-novel binding molecules based on human gamma-B-crystallin, an all beta-sheet protein. J Mol Biol (2007) 0.86
Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness. Ophthalmic Surg Lasers Imaging Retina (2016) 0.86
Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications. Angiogenesis (2012) 0.86
Pseudoexfoliation: High risk factors for zonule weakness and concurrent vitrectomy during phacoemulsification. J Cataract Refract Surg (2010) 0.86